Selecting the right patient for tumor therapy

Research output: Contribution to journalShort survey

23 Citations (Scopus)

Abstract

Two clinical studies have identified mutations affecting the EGF receptor in lung cancers from patients who respond robustly to gefitinib, a small-molecule inhibitor of the receptor tyrosine kinase. This work highlights the importance of conducting clinical trials with an eye to delivering molecule-targeted therapeutics to those patients most likely to benefit.

Original languageEnglish (US)
Pages (from-to)577-578
Number of pages2
JournalNature Medicine
Volume10
Issue number6
DOIs
StatePublished - Jun 1 2004

Fingerprint

Patient Rights
Tumors
Molecules
Receptor Protein-Tyrosine Kinases
Epidermal Growth Factor Receptor
Lung Neoplasms
Neoplasms
Clinical Trials
Mutation
Therapeutics
gefitinib
Clinical Studies

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Selecting the right patient for tumor therapy. / Arteaga, Carlos L.

In: Nature Medicine, Vol. 10, No. 6, 01.06.2004, p. 577-578.

Research output: Contribution to journalShort survey

@article{777f83b8005e45768d1da032fd4581b6,
title = "Selecting the right patient for tumor therapy",
abstract = "Two clinical studies have identified mutations affecting the EGF receptor in lung cancers from patients who respond robustly to gefitinib, a small-molecule inhibitor of the receptor tyrosine kinase. This work highlights the importance of conducting clinical trials with an eye to delivering molecule-targeted therapeutics to those patients most likely to benefit.",
author = "Arteaga, {Carlos L.}",
year = "2004",
month = "6",
day = "1",
doi = "10.1038/nm0604-577",
language = "English (US)",
volume = "10",
pages = "577--578",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Selecting the right patient for tumor therapy

AU - Arteaga, Carlos L.

PY - 2004/6/1

Y1 - 2004/6/1

N2 - Two clinical studies have identified mutations affecting the EGF receptor in lung cancers from patients who respond robustly to gefitinib, a small-molecule inhibitor of the receptor tyrosine kinase. This work highlights the importance of conducting clinical trials with an eye to delivering molecule-targeted therapeutics to those patients most likely to benefit.

AB - Two clinical studies have identified mutations affecting the EGF receptor in lung cancers from patients who respond robustly to gefitinib, a small-molecule inhibitor of the receptor tyrosine kinase. This work highlights the importance of conducting clinical trials with an eye to delivering molecule-targeted therapeutics to those patients most likely to benefit.

UR - http://www.scopus.com/inward/record.url?scp=2942722368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942722368&partnerID=8YFLogxK

U2 - 10.1038/nm0604-577

DO - 10.1038/nm0604-577

M3 - Short survey

C2 - 15170197

AN - SCOPUS:2942722368

VL - 10

SP - 577

EP - 578

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 6

ER -